SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 54.55-3.6%3:27 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Young who wrote (6936)8/19/2002 10:51:37 AM
From: Vector1  Read Replies (2) of 52153
 
Michael, OSIP is down 46%. Clearly the IRESSA failure has implications for the likelihood of success of Tarceva. They have similar mechanisms of action (EGFR blocking). Erbitux also has a similar mechanism but is not considered as close a cousin. Would love to hear from the scientists on this board on what the IRESSA study means for the likelihood of success of Tarceva. Major impact on the valuations of OSIP and DNA.

V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News